Bio-Rad Laboratories
What analysts say:
- Buy, sell, or hold?: The majority of analysts back Bio-Rad Laboratories as a buy. But with 60% of analysts rating it a buy, Bio-Rad Laboratories is still below the mean analyst rating of its nearest 10 competitors, which average 60.3% buys. Analysts don't like Bio-Rad Laboratories as much as competitor Cepheid overall. Ten out of 14 analysts rate Cepheid a buy compared to three of five for Bio-Rad Laboratories.
- Revenue forecasts: On average, analysts predict $562.1 million in revenue this quarter. That would represent a rise of 5.3% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate is earnings of $1.65 per share. Estimates range from $1.51 to $1.79.
What our community says:
CAPS All-Stars are enthusiastically backing the stock, with 100% giving it an "outperform" rating. The greater community concurs with the All-Stars, as 95.7% give it a rating of "outperform." Even with a robust four out of five stars, Bio-Rad Laboratories' CAPS rating falls a little short of the community's upbeat outlook.
Management:
Bio-Rad Laboratories' profit has risen year over year by an average of 20.5% over the past five quarters. Revenue has now gone up for three straight quarters.
Quarter | Q3 | Q2 | Q1 | Q4 |
Gross Margin | 57.3% | 56.2% | 57.2% | 56.2% |
Operating Margin | 14.3% | 13.1% | 13.8% | 14.6% |
Net Margin | 8.9% | 7.7% | 6.8% | 12.7% |
We can help you keep tabs on your companies with My Watchlist, our free, personalized service. Add Bio-Rad Laboratories now.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Earnings estimates provided by Zacks.